- New Panadol pack sizes appearing on shelf in retail stores and pharmacies across Australia
- Complying with the Therapeutic Goods Administration (TGA) scheduling decision for paracetamol that seeks to minimise the risk of harm from intentional misuse
- Haleon is acting responsibly by implementing this roll out well ahead of the legislative effective date
- New pack sizes will start to appear on shelf from late October 2024
- Consumers can be reassured that there is no change to the suitability profile and efficacy of paracetamol for pain relief when used as directed
Friday 25 October 2024, Sydney, Australia: Haleon, the makers of Panadol (containing paracetamol as the active ingredient), is rolling out new Panadol pack sizes ahead of upcoming legislative changes that aim to minimise the risk of harm from intentional misuse of paracetamol in Australia.
The changes are in response to the decision by the TGA in 2023 to reduce the maximum available pack sizes of paracetamol-containing medicines for general sale and self-selection in pharmacies.
From 1 February 2025, the changes are as follows:
- Nationally, packs of paracetamol-containing products available for general sale in supermarkets and convenience stores will contain a maximum of 16 capsules or tablets.
- In Western Australia and Queensland, packs of paracetamol-containing products available for self-selection in pharmacy, will contain a maximum of 16 capsules or tablets.*
- In states and territories other than Western Australia and Queensland, packs of paracetamol-containing products available for self-selection in pharmacies, will contain a maximum of 50 capsules or tablets.
- In pharmacies, packs of paracetamol-containing products of more than 16 and up to 100 capsules/tablets in Western Australia and Queensland, and more than 50 and up to 100 capsules/tablets in all other states and territories, will be available behind the counter, after speaking with a pharmacist.
These changes apply to single active and paracetamol-containing combination tablets and capsules, such as cold and flu preparations.
The legislative effective date for changes to scheduling controls for access and sale is 1 February 2025, but some of the new Panadol packs have already started to appear on shelves.
Paracetamol remains a suitable and effective pain relief option. It is the most widely used pain relief medicine available without a prescription. Paracetamol has wide-ranging suitability† for the majority of Australians.1
Elena Pintado, Head of Pain from Haleon ANZ, says the company has been working hard behind the scenes to implement these changes and ensure no disruption to supply.
"Our focus is always on the health of Australians and facilitating responsible self-care. As the makers of Panadol, Australia's number one trusted pain relief brand2, we take our responsibility very seriously to ensure Australians can continue to access Panadol without disruption as these changes come into effect,” said Ms Pintado.
“It is important to provide reassurance to Australians that there is no change to the suitability profile and efficacy of paracetamol for pain relief when used as directed,” added Ms Pintado.
Painaustralia Ambassador and former National Health Reporter for the ABC, Sophie Scott, in paid partnership with Haleon Australia, encourages people to always follow the instructions on the pack when taking over-the-counter medicines to relieve pain.
“Everyday pain affects a large number of Australians and paracetamol is widely used to manage it. Paracetamol is effective for everyday pain relief when used as directed. It is important that we follow the instructions on the pack and consult a healthcare professional if our pain persists,” added Ms Scott.
Over the counter analgesics should not be used for more than a few days at a time. If pain persists it is important to consult a healthcare professional.
Always read the label and follow the directions for use. Incorrect use could be harmful.
ENDS
MEDIA CONTACTS
|
Sarah Rumsey Palin Communications 0488 060 047 |
Ellen Hahn Palin Communications 0414 674 743 |
ABOUT HALEON
Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon’s product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands are built on trusted science, innovation and deep human understanding. For more information, please visit www.haleon.com.
REFERENCES
- Clarke, G. D. et al, (2008). Using suitability profiles to better inform consumers’ choice of commonly used over-the counter analgesics. Int J Pharm Pract, 16(5), 333-336 (GSK sponsored study). Accessed June 2024.
- Reader’s Digest Trusted Brands Survey 2024
Panadol contains paracetamol. Use: For the temporary relief of pain. Reduces fever.
* Queensland and Western Australia Poisons regulations governing the storage and display of medicines available only in Pharmacies (i.e., S2 medicines) differ from the other states and territories.
†Suitability based on criteria derived from contraindications, warnings and precautions from the product labelling and prescribing information for OTC paracetamol, and on Australian population demographics of 2006.